Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Multi-omics signature of brain amyloid deposition in asymptomatic individuals at-risk for Alzheimer's disease: The INSIGHT-preAD study.

Xicota L, Ichou F, Lejeune FX, Colsch B, Tenenhaus A, Leroy I, Fontaine G, Lhomme M, Bertin H, Habert MO, Epelbaum S, Dubois B, Mochel F, Potier MC; INSIGHT study group.

EBioMedicine. 2019 Sep;47:518-528. doi: 10.1016/j.ebiom.2019.08.051. Epub 2019 Sep 3.

2.

Effect of epigallocatechin gallate on the body composition and lipid profile of down syndrome individuals: Implications for clinical management.

Xicota L, Rodríguez J, Langohr K, Fitó M, Dierssen M, de la Torre R; TESDAD study group.

Clin Nutr. 2019 Jun 8. pii: S0261-5614(19)30255-9. doi: 10.1016/j.clnu.2019.05.028. [Epub ahead of print]

PMID:
31229326
3.

A phase 1, randomized double-blind, placebo controlled trial to evaluate safety and efficacy of epigallocatechin-3-gallate and cognitive training in adults with Fragile X syndrome.

de la Torre R, de Sola S, Farré M, Xicota L, Cuenca-Royo A, Rodriguez J, León A, Langohr K, Gomis-González M, Hernandez G, Esteba S, Del Hoyo L, Sánchez-Gutiérrez J, Cortés MJ, Ozaita A, Espadaler JM, Novell R, Martínez-Leal R, Milá M, Dierssen M; TESXF Study Group.

Clin Nutr. 2020 Feb;39(2):378-387. doi: 10.1016/j.clnu.2019.02.028. Epub 2019 Mar 25.

PMID:
30962103
4.

Neutrophil hyperactivation correlates with Alzheimer's disease progression.

Dong Y, Lagarde J, Xicota L, Corne H, Chantran Y, Chaigneau T, Crestani B, Bottlaender M, Potier MC, Aucouturier P, Dorothée G, Sarazin M, Elbim C.

Ann Neurol. 2018 Feb;83(2):387-405. doi: 10.1002/ana.25159.

PMID:
29369398
5.

Cannabis Users Show Enhanced Expression of CB1-5HT2A Receptor Heteromers in Olfactory Neuroepithelium Cells.

Galindo L, Moreno E, López-Armenta F, Guinart D, Cuenca-Royo A, Izquierdo-Serra M, Xicota L, Fernandez C, Menoyo E, Fernández-Fernández JM, Benítez-King G, Canela EI, Casadó V, Pérez V, de la Torre R, Robledo P.

Mol Neurobiol. 2018 Aug;55(8):6347-6361. doi: 10.1007/s12035-017-0833-7. Epub 2018 Jan 2.

PMID:
29294249
6.

VNTR-DAT1 and COMTVal158Met Genotypes Modulate Mental Flexibility and Adaptive Behavior Skills in Down Syndrome.

Del Hoyo L, Xicota L, Langohr K, Sánchez-Benavides G, de Sola S, Cuenca-Royo A, Rodriguez J, Rodríguez-Morató J, Farré M, Dierssen M, de la Torre R; TESDAD Study Group.

Front Behav Neurosci. 2016 Oct 17;10:193. eCollection 2016.

7.

Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial.

de la Torre R, de Sola S, Hernandez G, Farré M, Pujol J, Rodriguez J, Espadaler JM, Langohr K, Cuenca-Royo A, Principe A, Xicota L, Janel N, Catuara-Solarz S, Sanchez-Benavides G, Bléhaut H, Dueñas-Espín I, Del Hoyo L, Benejam B, Blanco-Hinojo L, Videla S, Fitó M, Delabar JM, Dierssen M; TESDAD study group.

Lancet Neurol. 2016 Jul;15(8):801-810. doi: 10.1016/S1474-4422(16)30034-5.

PMID:
27302362
8.

Semantic Verbal Fluency Pattern, Dementia Rating Scores and Adaptive Behavior Correlate With Plasma Aβ42 Concentrations in Down Syndrome Young Adults.

Hoyo LD, Xicota L, Sánchez-Benavides G, Cuenca-Royo A, de Sola S, Langohr K, Fagundo AB, Farré M, Dierssen M, de la Torre R.

Front Behav Neurosci. 2015 Nov 18;9:301. doi: 10.3389/fnbeh.2015.00301. eCollection 2015.

9.

Potential Role of (-)-Epigallocatechin-3-Gallate (EGCG) in the Secondary Prevention of Alzheimer Disease.

Xicota L, Rodriguez-Morato J, Dierssen M, de la Torre R.

Curr Drug Targets. 2017;18(2):174-195. doi: 10.2174/1389450116666150825113655. Review.

PMID:
26302801
10.

A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials.

de Sola S, de la Torre R, Sánchez-Benavides G, Benejam B, Cuenca-Royo A, Del Hoyo L, Rodríguez J, Catuara-Solarz S, Sanchez-Gutierrez J, Dueñas-Espin I, Hernandez G, Peña-Casanova J, Langohr K, Videla S, Blehaut H, Farre M, Dierssen M; TESDAD Study Group.

Front Psychol. 2015 Jun 4;6:708. doi: 10.3389/fpsyg.2015.00708. eCollection 2015.

11.

Potential role of olive oil phenolic compounds in the prevention of neurodegenerative diseases.

Rodríguez-Morató J, Xicota L, Fitó M, Farré M, Dierssen M, de la Torre R.

Molecules. 2015 Mar 13;20(3):4655-80. doi: 10.3390/molecules20034655. Review.

Supplemental Content

Loading ...
Support Center